Seres Therapeutics (MCRB) Misses Q2 EPS by 218c

Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($2.27), $2.18 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
• SentinelOne, Inc. (S) Tops Q2 EPS by 1c; offers guidance
• Autodesk (ADSK) Tops Q2 EPS by 18c, Beats on Revenue; Offers FY27 EPS Guidance